Molecular Medicine

, Volume 17, Issue 5–6, pp 568–573 | Cite as

Novel Aspects of Fibrin(ogen) Fragments during Inflammation

  • Carla Jennewein
  • Nguyen Tran
  • Patrick Paulus
  • Peter Ellinghaus
  • Johannes Andreas Eble
  • Kai Zacharowski
Review Article


Coagulation is fundamental for the confinement of infection and/or the inflammatory response to a limited area. Under pathological inflammatory conditions such as arthritis, multiple sclerosis or sepsis, an uncontrolled activation of the coagulation system contributes to inflammation, microvascular failure and organ dysfunction. Coagulation is initiated by the activation of thrombin, which, in turn, triggers fibrin formation by the release of fibrinopeptides. Fibrin is cleaved by plasmin, resulting in clot lysis and an accompanied generation of fibrin fragments such as D and E fragments. Various coagulation factors, including fibrinogen and/or fibrin (fibrin(ogen)) and also fibrin degradation products, modulate the inflammatory response by affecting leukocyte migration and cytokine production. Fibrin fragments are mostly proinflammatory, however, Bβ15–42 in particular possesses potential antiinflammatory effects. Bβ15–42 inhibits Rho-kinase activation by dissociating Fyn from Rho and, hence prevents stress-induced loss of endothelial barrier function and also leukocyte migration. This article summarizes the state-of-the-art in inflammatory modulation by fibrin(ogen) and fibrin fragments. However, further research is required to gain better understanding of the entire role fibrin fragments play during inflammation and, possibly, disease development.



This work is supported by the Deutsche Forschungsgesellschaft (SFB834, project B4). DISCLOSURE


  1. 1.
    Levi M. (2010) The coagulant response in sepsis and inflammation. Haemostaseologie. 30:10–6.CrossRefGoogle Scholar
  2. 2.
    Flick MJ, et al. (2007) Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J.Clin. Invest. 117:3224–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Paul J, Strickland S, Melchor JP. (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J.Exp. Med. 204:1999–2008.CrossRefPubMedGoogle Scholar
  4. 4.
    Adams RA, et al. (2007) The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204:571–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Boos CJ, Goon PK, Lip GY. (2006) The endothelium, inflammation, and coagulation in sepsis. Clin. Pharmacol. Ther. 79:20–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Levi M, van der Poll T, Buller HR. (2004) Bidirectional relation between inflammation and coagulation. Circulation. 109:2698–704.CrossRefGoogle Scholar
  7. 7.
    Iba T, et al. (2005) Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock. 23:25–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Fareed J, et al. (1998) Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin. Chem. 44:1845–53.PubMedGoogle Scholar
  9. 9.
    Medcalf RL. (2007) Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J.Thromb. Haemost. 5 Suppl 1:132–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Knoebl P. (2010) Blood coagulation disorders in septic patients. Wien. Med. Wochenschr. 160:129–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Pawlinski R, Mackman N. (2010) Cellular sources of tissue factor in endotoxemia and sepsis. Thromb. Res. 125 Suppl 1:S70–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Levi M, et al. (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest. 93:114–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Erlich JH, et al. (2000) Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am. J. Pathoi. 157:1849–62.CrossRefGoogle Scholar
  14. 14.
    Cunningham MA, et al. (2000) Protease-activated receptor 1 mediates thrombin-dependent, cellmediated renal inflammation in crescentic glomerulonephritis. J. Exp. Med. 191:455–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Yang YH, et al. (2005) Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum. 52:1325–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Busso N, et al. (2008) Essential role of platelet activation via protease activated receptor 4 in tissue factor-initiated inflammation. Arthritis Res. Ther. 10:R42.CrossRefPubMedGoogle Scholar
  17. 17.
    Mosesson MW. (2005) Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 3:1894–904.CrossRefPubMedGoogle Scholar
  18. 18.
    Lord ST. (2007) Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr. Opin. Hematol. 14:236–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Olexa SA, Budzynski AZ, Doolittle RF, Cottrell BA, Greene TC. (1981) Structure of fragment E species from human cross-linked fibrin. Biochemistry. 20:6139–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Smith EB, Keen GA, Grant A, Stirk C. (1990) Fate of fibrinogen in human arterial intima. Arteriosclerosis. 10:263–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Walker JB, Nesheim ME. (1999) The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J. Biol. Chem. 274:5201–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Hurley JV. (1964) Substances promoting leukocyte emigration. Ann. N. Y. Acad. Sci. 116:918–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Colvin RB, Johnson RA, Mihm MC Jr, Dvorak HF. (1973) Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J. Exp. Med. 138:686–98.CrossRefPubMedGoogle Scholar
  24. 24.
    Barnhart MI, Riddle JM, Bluhm GB, Quintana C. (1967) Fibrin promotion and lysis in arthritic joints. Ann. Rheum. Dis. 26:206–18.CrossRefPubMedGoogle Scholar
  25. 25.
    Qi J, Goralnick S, Kreutzer DL. (1997) Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood. 90:3595–602.PubMedGoogle Scholar
  26. 26.
    Trezzini C, Schuepp B, Maly FE, Jungi TW. (1991) Evidence that exposure to fibrinogen or to antibodies directed against Mac-1 (CD11b/CD18; CR3) modulates human monocyte effector functions. Br. J. Haematol. 77:16–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Jensen T, et al. (2007) Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells. Thromb. Haemost. 97:822–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Fan ST, Edgington TS. (1993) Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J. Immunol. 150:2972–80.PubMedGoogle Scholar
  29. 29.
    Smiley ST, King JA, Hancock WW. (2001) Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167:2887–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Kaneider NC, Mosheimer B, Gunther A, Feistritzer C, Wiedermann CJ. (2010) Enhancement of fibrinogen-triggered pro-coagulant activation of monocytes in vitro by matrix metallo-proteinase-9. Thromb. J. 8:2.CrossRefPubMedGoogle Scholar
  31. 31.
    Kreuzer J, et al. (1996) Fibrinogen promotes monocyte adhesion via a protein kinase C dependent mechanism. J. Mol. Med. 74:161–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Perez RL, Roman J. (1995) Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J. Immunol. 154:1879–87.PubMedGoogle Scholar
  33. 33.
    Sitrin RG, Pan PM, Srikanth S, Todd RF 3rd. (1998) Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J. Immunol. 161:1462–70.PubMedGoogle Scholar
  34. 34.
    Li Q, Verma IM. (2002) NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2:725–34.CrossRefPubMedGoogle Scholar
  35. 35.
    Hynes RO. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11–25.CrossRefGoogle Scholar
  36. 36.
    Altieri DC. (1999) Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb. Haemost. 82:781–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Altieri DC, et al. (1990) A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J. Biol. Chem. 265:12119–22.PubMedGoogle Scholar
  38. 38.
    Ugarova TP, et al. (1998) Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen. J. Biol. Chem. 273:22519–27.CrossRefPubMedGoogle Scholar
  39. 39.
    Yakovlev S, Zhang L, Ugarova T, Medved L. (2005) Interaction of fibrin(ogen) with leukocyte receptor alpha M beta 2 (Mac-1): further characterization and identification of a novel binding region within the central domain of the fibrinogen gamma-module. Biochemistry. 44:617–26.CrossRefPubMedGoogle Scholar
  40. 40.
    Forsyth CB, Solovjov DA, Ugarova TP, Plow EF. (2001) Integrin alpha(M)beta(2)-mediated cell migration to fibrinogen and its recognition pep- tides. J. Exp. Med. 193:1123–33.CrossRefPubMedGoogle Scholar
  41. 41.
    Altieri DC, Plescia J, Plow EF. (1993) The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion. J. Biol. Chem. 268:1847–53.PubMedGoogle Scholar
  42. 42.
    Flick MJ, et al. (2004) Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaM-beta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invest. 113:1596–606.CrossRefPubMedGoogle Scholar
  43. 43.
    Languino LR, et al. (1993) Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 73:1423–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Harley SL, Sturge J, Powell JT. (2000) Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:652–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Lishko VK, Burke T, Ugarova T. (2007) Antiadhesive effect of fibrinogen: a safeguard for thrombus stability. Blood. 109:1541–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Lishko VK, Yermolenko IS, Ugarova TP. (2010) Plasminogen on the surfaces of fibrin clots prevents adhesion of leukocytes and platelets. J. Thromb. Haemost. 8:799–807.CrossRefPubMedGoogle Scholar
  47. 47.
    Szaba FM, Smiley ST. (2002) Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 99:1053–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Petzelbauer P, et al. (2005) The fibrin-derived pep-tide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat. Med. 11:298–304.CrossRefPubMedGoogle Scholar
  49. 49.
    Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M. (1998) Serum matrix metallopro-teinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 16:533–40.PubMedGoogle Scholar
  50. 50.
    Kazura JW, Wenger JD, Salata RA, Budzynski AZ, Goldsmith GH. (1989) Modulation of polymor-phonuclear leukocyte microbicidal activity and oxidative metabolism by fibrinogen degradation products D and E. J. Clin. Invest. 83:1916–24.CrossRefPubMedGoogle Scholar
  51. 51.
    Richardson DL, Pepper DS, Kay AB. (1976) Chemotaxis for human monocytes by fibrinogen-derived peptides. Br. J. Haematol. 32:507–13.CrossRefPubMedGoogle Scholar
  52. 52.
    Senior RM, Skogen WF, Griffin GL, Wilner GD. (1986) Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J. Clin. Invest. 77:1014–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Singh TM, Kadowaki MH, Glagov S, Zarins CK. (1990) Role of fibrinopeptide B in early atherosclerotic lesion formation. Am. J. Surg. 160:156–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Persson K, Russell W, Morgelin M, Herwald H. (2003) The conversion of fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to the generation of proinflammatory fibrinopeptides. J. Biol. Chem. 278:31884–90.CrossRefPubMedGoogle Scholar
  55. 55.
    Ruhenstroth-Bauer G, Scherer R, Hornberger M, Tongendorff G. (1981) Demonstration of anti-inflammatory activity of fibrinogen and fibrinopeptides in rats. Inflammation. 5:343–51.CrossRefPubMedGoogle Scholar
  56. 56.
    Hamaguchi M, et al. (1991) FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line. Blood. 77:94–100.PubMedGoogle Scholar
  57. 57.
    Robson SC, Shephard EG, Kirsch RE. (1994) Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br. J. Haematol. 86:322–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Lee ME, Rhee KJ, Nham SU. (1999) Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages. Mol. Cells. 9:7–13.PubMedGoogle Scholar
  59. 59.
    Lee ME, Kweon SM, Ha KS, Nham SU. (2001) Fibrin stimulates microfilament reorganization and IL-1beta production in human monocytic THP-1 cells. Mol. Cells. 11:13–20.PubMedGoogle Scholar
  60. 60.
    Thompson WD, et al. (1992) Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J. Pathol. 168:47–53.CrossRefPubMedGoogle Scholar
  61. 61.
    Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. (2001) Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis. 4:269–75.CrossRefPubMedGoogle Scholar
  62. 62.
    Naito M, Stirk CM, Smith EB, Thompson WD. (2000) Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. Thromb. Res. 98:165–74.CrossRefPubMedGoogle Scholar
  63. 63.
    Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE. (2000) Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res. 60:4719–24.PubMedGoogle Scholar
  64. 64.
    Vali Z, Scheraga HA. (1988) Localization of the binding site on fibrin for the secondary binding site of thrombin. Biochemistry. 27:1956–63.CrossRefPubMedGoogle Scholar
  65. 65.
    Bach TL, Barsigian C, Yaen CH, Martinez J. (1998) Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J. Biol. Chem. 273:30719–28.CrossRefPubMedGoogle Scholar
  66. 66.
    Skogen WF, Senior RM, Griffin GL, Wilner GD. (1988) Fibrinogen-derived peptide B beta 1–42 is a multidomained neutrophil chemoattractant. Blood. 71:1475–9.PubMedGoogle Scholar
  67. 67.
    Lalla RV, Tanzer ML, Kreutzer DL. (2003) Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells. Arch. Oral Biol. 48:263–71.CrossRefPubMedGoogle Scholar
  68. 68.
    Atar D, et al. (2009) Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J. Am. Coll. Cardiol. 53:720–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Roesner JP, et al. (2009) Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit. Care Med. 37:598–605.CrossRefPubMedGoogle Scholar
  70. 70.
    Gröger M, et al. (2009) Peptide Bbeta(15–42) preserves endothelial barrier function in shock. PLoS One. 4:e5391.CrossRefPubMedGoogle Scholar
  71. 71.
    Wiedemann D, et al. (2010) The fibrin-derived peptide Bbeta(15–42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation. 89:824–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Staton CA, et al. (2004) Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood. 103:601–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Krajewska E, et al. (2010) A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo. Br. J. Cancer. 102:594–601.CrossRefPubMedGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Carla Jennewein
    • 1
  • Nguyen Tran
    • 1
  • Patrick Paulus
    • 1
  • Peter Ellinghaus
    • 2
  • Johannes Andreas Eble
    • 3
  • Kai Zacharowski
    • 1
  1. 1.Clinic of Anesthesiology, Intensive Care Medicine and Pain TherapyJW-Goethe-University Hospital FrankfurtFrankfurt am MainGermany
  2. 2.Bayer Schering Pharma AGWuppertalGermany
  3. 3.Center of Molecular Medicine, Excellence Cluster Cardio-Pulmonary SystemGoethe-University Hospital FrankfurtFrankfurt am MainGermany

Personalised recommendations